Continue saving this Cyber Monday 🥳

These sales are still running

Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy VBI Vaccines stock in Canada | $2.88

Own VBI Vaccines shares in just a few minutes.

Posted

Fact checked

VBI Vaccines Inc is a biotechnology business based in the US. VBI Vaccines shares (VBIV.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $2.88 – a decrease of 2.37% over the previous week. VBI Vaccines employs 123 staff and has a trailing 12-month revenue of around $1.5 million.

How to buy shares in VBI Vaccines

  1. Choose a platform. If you're a beginner, our share-dealing table below can help you choose.
  2. Open your account. You'll need your ID, bank details and national insurance number.
  3. Confirm your payment details. You'll need to fund your account with a bank transfer, debit card or credit card.
  4. Search the platform for stock code: VBIV in this case.
  5. Research VBI Vaccines shares. The platform should provide the latest information available.
  6. Buy your VBI Vaccines shares. It's that simple.

How has Coronavirus impacted VBI Vaccines's share price?

Since the stock market crash in March caused by coronavirus, VBI Vaccines's share price has had significant positive movement.

Its last market close was $2.88, which is 48.26% up on its pre-crash value of $1.49 and 317.39% up on the lowest point reached during the March crash when the shares fell as low as $0.69.

If you had bought $1,000 worth of VBI Vaccines shares at the start of February 2020, those shares would have been worth $533.09 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth $2,117.64.

VBI Vaccines share price

Use our graph to track the performance of VBIV stocks over time.

VBI Vaccines shares at a glance

Information last updated 2020-11-25.
Latest market close $2.88
52-week range $0.69 - $6.93
50-day moving average $2.6253
200-day moving average $3.1279
Wall St. target price $8.25
Dividend yield N/A (0%)
Earnings per share (TTM) $-0.758

Compare online trading platforms

Name Product Available asset types Stock Fee Option Fee Account Fee ETF Transaction Cost
Questrade
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs, International Equities, IPOs, Precious Metals
$4.95 - $9.95
$9.95 + $1 per contract
$0
Free
Opt for self-directed investing and save on fees or get a pre-built portfolio and take some of the guesswork out.
Interactive Brokers
Stocks, Bonds, Options, Mutual Funds, ETFs, Currencies, Futures, Precious Metals
Min. $1.00, Max. 0.5% of trade value
$1.50 min. per order
$0 (if monthly commissions are equal to or greater than US$10.00)
Min. $1.00, Max. 0.5% of trade value
Access market data 24 hours a day, six days a week and invest in global stocks, options, futures, currencies, bonds and funds from one single account.
Wealthsimple Trade
Stocks, ETFs
$0
N/A
$0
Free
Buy and sell thousands of US and Canadian stocks and ETFs commission-free with Wealthsimple Trade.
loading

Compare up to 4 providers

Name Product Minimum deposit to invest Funding methods Management fee Available asset types
CI Direct Investing (formerly WealthBar)
$1,000
Direct deposit, Bank transfer
0.35% - 0.60%
Mutual Funds, ETFs
CI Direct Investing offers access to an exclusive and personalized investment portfolio. Get up to $10,000 managed free for a year when you sign up for your first CI Direct Investing account and fund your account.
Moka
$0
Automatic bank withdrawals
$3/month
ETFs
The Moka app rounds up every purchase you make to the nearest dollar and invests the spare change into low-cost exchange-traded funds (ETFs).
Justwealth
$5,000
Direct deposit, Bank transfer, Automatic bank withdrawals
0.50%
ETFs
Receive a cash bonus of $50.00-$225.00 when you open a new Justwealth account. RESP accounts require no minimum deposit to begin investing.
Wealthsimple Invest
$1
Direct deposit, Bank transfer
0.40% - 0.50%
Stocks, Bonds, ETFs, Commodities
Get a $50 bonus when you open and fund your first Wealthsimple Invest account with a minimum initial deposit of at least $500. Trade and Cash accounts are not eligible.
loading

Compare up to 4 providers

Name Product Minimum Opening Deposit Commission Available Markets Platforms
Forex.com
US$100
Minimum US$25
Forex
Metals
Commodities
Indices
Shares
Forex.com Desktop, Forex.com Web Trading, Forex.com Mobile Trading, MetaTrader 4
CFDs are leveraged products which involves greater risk than using cash resources only. You could lose all or more of your initial investment. Trade 80+ currency pairs and 220+ CFDs in equities, commodities and indices on Forex.com.
loading

Compare up to 4 providers

Is it a good time to buy VBI Vaccines stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

VBI Vaccines price performance over time

Historical closes compared with the last close of $2.88

1 week (2020-11-20) 4.73%
1 month (2020-10-30) 22.55%
3 months (2020-08-28) -27.82%
6 months (2020-05-29) 32.11%
1 year (2019-11-29) 220.61%
2 years (2018-11-29) 81.13%
3 years (2017-11-29) -40.12%
5 years (2015-11-27) 1,958.61%

VBI Vaccines financials

Revenue TTM USD$1.5 million
Gross profit TTM USD$-5,683,000
Return on assets TTM -14.92%
Return on equity TTM -31.74%
Profit margin 0%
Book value $0.685
Market capitalisation USD$602.7 million

TTM: trailing 12 months

How to short and sell VBI Vaccines shares

  1. Create a CFD or spread betting account.
  2. Search for the stock code. E.g. "VBIV.US"
  3. Choose your position size.
  4. Select "sell" rather than "buy".
  5. Confirm your position and keep tabs on it. You may wish to set limits on your position.

There are currently 42.7 million VBI Vaccines shares held short by investors – that's known as VBI Vaccines's "short interest". This figure is 7.8% up from 39.6 million last month.

There are a few different ways that this level of interest in shorting VBI Vaccines shares can be evaluated.

VBI Vaccines's "short interest ratio" (SIR)

VBI Vaccines's "short interest ratio" (SIR) is the quantity of VBI Vaccines shares currently shorted divided by the average quantity of VBI Vaccines shares traded daily (recently around 4.5 million). VBI Vaccines's SIR currently stands at 9.39. In other words for every 100,000 VBI Vaccines shares traded daily on the market, roughly 9390 shares are currently held short.

However VBI Vaccines's short interest can also be evaluated against the total number of VBI Vaccines shares, or, against the total number of tradable VBI Vaccines shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case VBI Vaccines's short interest could be expressed as 0.18% of the outstanding shares (for every 100,000 VBI Vaccines shares in existence, roughly 180 shares are currently held short) or 0.235% of the tradable shares (for every 100,000 tradable VBI Vaccines shares, roughly 235 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against VBI Vaccines.

Find out more about how you can short VBI Vaccines stock.

VBI Vaccines share dividends

We're not expecting VBI Vaccines to pay a dividend over the next 12 months. However, you can browse other dividend-paying shares in our guide.

Have VBI Vaccines's shares ever split?

VBI Vaccines's shares were split on a 1:40 basis on 2 May 2016. So if you had owned 40 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your VBI Vaccines shares – just the quantity. However, indirectly, the new 3900% higher share price could have impacted the market appetite for VBI Vaccines shares which in turn could have impacted VBI Vaccines's share price.

VBI Vaccines share price volatility

Over the last 12 months, VBI Vaccines's shares have ranged in value from as little as $0.69 up to $6.93. A popular way to gauge a stock's volatility is its "beta".

VBIV.US volatility(beta: 1.91)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while VBI Vaccines's is 1.9087. This would suggest that VBI Vaccines's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

VBI Vaccines overview

VBI Vaccines Inc., a biopharmaceutical company, develops and sells vaccines for the treatment of infectious diseases and immuno-oncology in Israel, the United States, and internationally. The company offers Sci-B-Vac, a prophylactic hepatitis B vaccine for adults, children, and newborns. It also engages in the development of VBI-2601 (BRII-179), an immunotherapeutic candidate for a functional cure of chronic hepatitis B. The company's enveloped virus-like particle (eVLP) platform technology allows for the development of eVLP vaccines that mimic the target virus to elicit a potent immune response. Its lead eVLP program candidates include VBI-1901, a glioblastoma vaccine immunotherapeutic candidate, which is in Phase I/IIa clinical study; and VBI-1501, a prophylactic cytomegalovirus vaccine candidate that has completed Phase I clinical trial. In addition, the company engages in the development of vaccine platforms and products for licensing to pharmaceutical companies and biotechnology companies. It primarily serves physicians and pharmacists through direct sales. VBI Vaccines Inc. has collaboration and license agreements with Brii Biosciences Limited; and GlaxoSmithKline Biologicals S.A. It also has a collaboration with the National Research Council of Canada to develop pan-coronavirus vaccine candidate targeting COVID-19, severe acute respiratory syndrome, and Middle East respiratory syndrome. The company was formerly known as SciVac Therapeutics Inc. and changed its name to VBI Vaccines Inc. in May 2016. VBI Vaccines Inc. is headquartered in Cambridge, Massachusetts.

Frequently asked questions

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, CFDs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading CFDs and forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More guides on Finder

Go to site